- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.06. | Exelixis' Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review | ||
| 22.06. | Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months | ||
| 22.06. | In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy | ||
| 22.06. | Merck's anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis | ||
| 22.06. | AbbVie inks $10.9B Apogee buyout to bag hotly tipped eczema prospect | ||
| 22.06. | Sanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum | ||
| 18.06. | Moderna's flu candidate sails through FDA advisory committee in unanimous votes | ||
| 18.06. | cAMPfield harvests $180M series A to advance oral IBD drug licensed from Newsoara | ||
| 18.06. | Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3 | ||
| 18.06. | Biogen inks $1B RayThera buyout to bag preclinical immunology assets | ||
| 17.06. | Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies | ||
| 17.06. | UniQure stock surges after FDA U-turn clears path to gene therapy filing | ||
| 16.06. | Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling | ||
| 16.06. | Eli Lilly's M&A spree continues with acquisition of non-opioid pain drugmaker 4E | ||
| 16.06. | PE firm Altaris scoops up AI drug development outfit Simulations Plus for $375M | ||
| 16.06. | Edgewise data power rival to BMS and Cytokinetics toward phase 3 | ||
| 16.06. | Merck inks $510M biobucks data generation partnership with Protillion | ||
| 16.06. | Adaptive plots splitting Pfizer-partnered drug discovery unit from diagnostics business | ||
| 15.06. | Spyre spies another edge for UC ambitions with midstage win for anti-TL1A antibody | ||
| 15.06. | Japan, South Korea challenge the West's place in research rankings: report | ||
| 15.06. | Intellia touts 'paradigm-shifting' phase 3 data for one-time HAE treatment | ||
| 15.06. | Amgen loses in Harbour antibody patent case, ordered to pay $20M+ | ||
| 15.06. | Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies | ||
| 15.06. | Traws defers midphase flu study after negative regulatory review | ||
| 15.06. | Soligenix axes lymphoma program after phase 3 setback, mulls M&A options |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.